

IN SILICO DOCKING APPROACH FOR ANTIATHEROSCLEROTIC ACTIVITY OF PHYTOCONSTITUENTS OF METHANOLIC EXTRACT OF *SOLANUM MELANOGENA*

G. Suresh Kumar^{1*} and B. Nivetha²

¹Department of Pharmaceutics, Excel College of Pharmacy, NH 544, Salem Main Road, Pallakapalayam, Sankari west post, Komarapalayam (T.K), Namakkal (DT)- 637303, Tamil Nadu, India.

²Department of Pharmacy Practice, Excel College of Pharmacy, NH 544, Salem Main Road, Pallakapalayam, Sankari west post, Komarapalayam (T.K), Namakkal (DT)- 637303, Tamil Nadu, India.

ABSTRACT

OBJECTIVE: Atherosclerosis is a chronic inflammatory disease characterized by changes in lipid metabolism within the arterial wall. Liver X alpha receptor is highly expressed in liver may control the metabolism of cholesterol and suppress the inflammatory genes, thus preventing atherosclerosis from being triggered. The *Solanum melongena* possess anti-atherosclerotic property by stimulating the intrahepatic metabolism of cholesterol, produces a marked drop in blood cholesterol level. The objective of the present study is to investigate the anti-atherosclerotic activity of the *methnolic extract of Solanum melongena peel* against Liver X alpha receptor by using iGEMDOCK. **METHODS:** Liver X alpha (Protein Date Bank ID - 3IPQ) 3 Dimensional structure was retrieved using the Protein Data Bank. Phytochemical molecules have been extracted from the Pubchem database and 2D chemical structures have been developed with a Chemskech program from the Smiles Notation. Comparative molecular docking simulation of the screened phytochemicals was carried out mainly with iGEMDOCKv2.1. **RESULTS:** Among the 13 phytochemicals, Catechin and Naringenin was found to be the top compound with highest docking score of -100.741kcal/mol and -92.7765 kcal/mol, respectively. **CONCLUSION:** Our analysis indicates phytochemicals derived from *methnolic extract of Solanum melongena peel* can serve as leads and atherosclerosis can be prevented.

Keywords: Atherosclerosis, *Solanum melonae*na, Liver X alpha receptor and iGEMDOCKv2.1.

INTRODUCTION

Atherosclerosis, being a chronic inflammatory condition, is becoming the leading cause of death in most developed countries.¹ Cardiovascular diseases (CVDs) such as myocardial infarction (heart attack), acute coronary syndrome, or stroke occur from plaque and lesion formation within the arteries.^{2,3} Hypercholesterolemia, hypertension, and obesity give the high risk of development

of CVDs. Statins are commonly used as a Clinical treatment for atherosclerosis because of their excellent effectiveness in reducing the degree of low lipoprotein density (LDL).^{4,5} Statins inhibit competitively the HMG-CoA reductase enzyme, which plays a major role in catalyzing the rate limiting step in cholesterol biosynthesis.⁶ Increased expression of hepatic LDL receptors is caused by decreased

concentration of hepatocyte cholesterol and helps clear LDL from circulation.^{7,8}

The liver X receptors (LXRs) are nuclear receptors regulated by endogenous oxysterols, which are oxidized cholesterol derivatives. This has two LXR isoforms, LXR α (NR1H3) and LXR β (NR1H2). All LXR α and LXR β control gene expression by binding to target gene-associated DNA sequences as heterodimers with retinoid X receptor (RXR), RXR α (NR2B1), RXR β (NR2B2) and RXR γ (NR2B3) isoforms. LXRs function as cholesterol sensors: when cellular oxysterols accumulate due to elevated cholesterol concentrations, LXR induces the transcription of genes that protect cells from overloading cholesterol. LXR's functions in cholesterol homeostasis regulation include bile acid synthesis and metabolism / excretion function, reverse cholesterol transport, cholesterol biosynthesis and uptake, and cholesterol absorption / excretion in the intestines. Often explored are the overlapping and distinct functions of the isoforms LXR α and LXR β and the possible use of LXRs as desirable targets for cardiovascular disease treatment.⁹

Nonetheless, statin intake causes adverse health effects such as hepatic damage and muscle toxicity.^{10,11} Additional side effects include myopathy, rhabdomyolysis and acute renal insufficiency.¹² Therefore, attention is now centered on plant-derived natural products which have antiatherosclerotic activity and can promote human health. It can potentially avoid potential health consequences due to long-term statin consumption. Over the last decades, several studies on bioactive compounds and their potential medicinal properties have been studied.^{13,14}

Solanum melongena belongs to the Solanaceae family and is an important flowering plant. There are 75 genera and over 2000 species within the family.¹⁵ Members are predominantly herbaceous plants, and the fruit is berry and the seeds have a large endosperm and are primarily cultivated for food and medicine purposes.¹⁶ *Solanum melongena* Linn (Garden egg) is a culinary vegetable that has been in use since ancient times in the Indian medicinal system. Specific parts of the plant are used in the treatment of inflammatory disease, heart failure, neuralgia, ulcer in nose and cholera. It also has analgesic, anticonvulsant, antipyretic, hypolipidemic activity¹⁵, anti-inflammatory activity. The plant can also be used to treat bronchitis and asthma.

The organic products of *Solanum melongena* are considered to contain distinctive groups of

phenolic phytochemicals (flavones, phenolic acids and anthocyanins) that can have beneficial effects on human health. By HPLC, it was identified that methanolic extract contains distinguishing proof of the diverse phenolic phytochemicals such as Gallic Acid, Catechin, Caffeic Acid, Syringic Acid, Rutin, Coumaric Acid, Vanillin, Ferulic Acid, Naringenin, Quercetin, Cinnamic Acid, Propyl Gallate, and DihydroxyisoFlavone.¹⁶

Hence, this research investigated the molecular association between the phytochemicals in the methanolic extract of *Solanum melongena* peel and the LXR α to prevent atherosclerosis by using iGEMDOCK¹⁷ via insilico docking.

METHODS

LXR α retrieval

The 3-Dimensional structure of LXR α (Protein Data Bank [PDB] ID – 3IPQ) was obtained using Protein Data Bank which could serve as the target molecular docking molecules. The structure was presented using Swiss PDB Viewer to build a deeper understanding of the molecule to use it as a target for the drug.

Building of herbal compounds

Thirteen phytochemicals identified from ethanol extract of *Solanum melongena* peel were screened against LXR α . List of phytochemicals identified are shown in Table 1. The phytochemical molecules were obtained from a pubchemic database and 2-D chemical structures were produced using the Chemsketch program from the SMILES notation. The structure was then converted to 3D, its geometries optimized and saved with an open babel server in MDL mol file format.

Primary docking simulation-iGEMDOCK.

Simulation of the phytochemicals was achieved using the docking module iGEMDOCK-v2.1.¹⁸ Using a generic evolutionary method algorithm, iGEMDOCK performs integrated scanning, docking, and post analysis. The binding site was prepared by iGEMDOCK tool to determine LXR α binding site. For both protein and ligand inputs the program needs .pdb file. Other parameters such as population size, generations and number of solutions were set at 200, 70 and 2 for Standard docking, respectively. The scoring function of iGEMDOCK can be illustrated as follows.

$$\text{Fitness} = \text{vdW} + \text{EHydrogen bond} + \text{EElectrostatic}$$

Where, vdW is Vander waal's energy (kcal/mol), H-bond is hydrogen bond energy (kcal/mol) and Elec is electrostatic forces

(kcal/mol) between the ligand and receptor protein.

The interaction profile tool in iGEMDOCK has performed post-analysis of the docked poses. The strength, forces of Vander waal, hydrogen bond energy, electrostatic force energy and interacting residues were obtained and tabulated.¹⁹ For further redock analysis, the top eight compound hits were selected based on total overall fitness and H-bond energies.

RESULTS AND DISCUSSION

Molecular docking studies of the Thirteen phytochemical compounds from the methanolic extract of *Solanum melongena* peel were performed primarily using iGEMDOCK v2.1 to establish binding free energy, energy split-up, and interactions between the ligands and the active site residues of LXR α . Among the studied ligands, Catechin and Naringenin were ranked in the first and second place with total binding energies of -100.741 kcal/mol and

-92.7765 kcal/mol, respectively. Catechin exhibit hydrogen bond energies of -21.3993 kcal/mol and showed hydrogen bond interactions with Ser-264, Met-298, Thr-302, Arg-305, Lys-317 respectively. Quercetin and Propylgallate shows significant binding energy of -89.1416 kcal/mol and -81.0235 kcal/mol with hydrogen bond energies of -18.6917 kcal/mol and -19.9087 kcal/mol. Quercetin shows three hydrogen bond interaction with His-397, Pro-398 and Arg-401 amino acid. and Propylgallate exhibit one hydrogen bond interaction with ARG-305 respectively.

The remaining phytochemicals Gallic Acid, Coffeic Acid, Syringic Acid, Rutin, Coumaric Acid, Vanillin, Ferulic Acid, Cinnamic Acid, and DihydroxyisoFlavone displayed total binding energies from -56.673 kcal/mol to -83.8911 kcal/mol without have any hydrogen bond energies.

Table 1: Primary Docking Results Illustrating Total Binding Energy, Energy Split Up And Interacting Residues Of Control And Test Ligands

Compound name	Primary Docking Analysis				Interacting residues
	Total binding energy kcal/mol	Vander Wall's Energy Kcal/mol	Hydrogen bond energy kcal/mol	Electrostatic bond energy kcal/mol	
Gallic Acid	-67.7006	-67.7006	0	0	Leu-260, Ser-264, Arg-305, Phe-315
Catechin	-100.741	-79.3418	-21.3993	0	Ser-264, Met-298, Thr-302, Arg-305, Lys-317, Leu-260, Ser-264, Glu-267, Arg-305, Phe-315, Leu-316
Coffeic Acid	-73.1332	-73.1332	0	0	Leu-260, Ala-261, Ser-264, Arg-305, Phe-315
Syringic Acid	-71.378	-71.378	0	0	Leu-260, Ala-26, Ser-264, Met-298, Arg-305, Phe-315
Rutin	-71.378	-71.378	0	0	Gln-221, Arg-304, Arg-304, Arg-305, Lys-317, Asp-353, Arg-304, Arg-305, Arg-305, Thr-314, Leu-316, Lys-317
Coumaric Acid	-65.3699	-65.3699	0	0	Phe-257, Leu-260, Ala-261, Phe-315
Vanillin	-56.673	-56.673	0	0	His-390, Val-393, Ser-394, Ile-395, his-396, His-397, Pro-398, his-399, Asp-400, Arg-401, -Leu-402, Met-403, Phe-404, Pro-405
Ferulic Acid	-70.6109	-70.6109	0	0	Leu-260, Ser-264, Arg-305, Phe-315
Naringenin	-92.7765	-92.7765	0	0	Phe-257, Leu-260, Ala-261, Ser-264, Met-298, Arg-305, Phe-315
Quercetin	-89.1416	-70.4499	-18.6917	0	His-397, Pro-398, Arg-401, His-390, Ser-394, Pro-398, Asp-400, Arg-401
Cinnamic Acid	-56.8387	-56.8387	0	0	Phe-257, Phe-326, Phe-335, Ile-339
Propyl Gallate	-81.0235	-61.1148	-19.9087	0	Arg-305, Leu-260, Ser-264, Phe-315
DihydroxyisoFlavone	-83.8911	-83.8911	0	0	Phe-257, Leu-260, Ala-261, Ser-264, Arg-305, Phe-315




Fig. 3: Interaction between LXRα and Quercetin




Fig. 4: Interaction between LXRα and Propylgallate

CONCLUSION

Catechin, Naringenin, Quercetin and Propylgallate from *Solanum melongena* were the best compound hits among the studied compounds. From the different interactions exhibited by these three compounds with the binding site residues of the LXR α it can be concluded that these compounds will structurally alter the expression of genes involved in the synthesis of hepatic bile and fatty acids, glucose metabolism and sterol efflux after binding with LXR α .

REFERENCES

- Margaret C. Burden: mortality, morbidity and risk factors. Global Status Report on Non Communicable Diseases. 2010.
- Navab M, Berliner JA and Watson AD. The Yin and Yang of oxidation in the development of the fatty streak. *Arteriosclerosis, Thrombosis, and Vascular Biology*. 1996;16(7):831–842.
- Ross R. Atherosclerosis—an inflammatory disease. *The New England Journal of Medicine*. 1999;340(2):115–126. Gould L, Rossouw JE, Santanello NC, Heyse JF and Furberg CD. Cholesterol reduction yields clinical benefit: impact of statin trials. *Circulation*. 1998;97(10): 946–952.
- Ray KK and Cannon CP. The potential relevance of the multiple lipid-independent (Pleiotropic) effects of statins in the management of acute coronary syndromes. *Journal of the American College of Cardiology*. 2005;46(8):1425–1433.
- Endo, Tsujita Y, Kuroda M and Tanzawa K. Inhibition of cholesterol synthesis in vitro and in vivo by ML 236A and ML 236B, competitive inhibitors of 3 hydroxy 3 methylglutaryl Coenzyme A reductase. *European Journal of Biochemistry*. 1977;77(1):31–36.
- Brown MS and Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis *Science*. 1986;232(4746):34– 47.
- Maron DJ, Lu GP and Cai NS. Cholesterol-lowering effect of a theaflavin-enriched green tea extract: a randomized controlled trial. *Archives of Internal Medicine*. 2003;163(12):1448–1453.
- Calkin, Anna C Tontonoz and Peter. Liver X receptor signaling pathways and atherosclerosis. *Arteriosclerosis, Thrombosis, and Vascular Biology*. 2010.
- Maron DJ, Lu GP and Cai NS. Cholesterol-lowering effect of a theaflavin-enriched green tea extract: a randomized controlled trial. *Archives of Internal Medicine*. 2003;163(12):1448–1453.
- Bradford RH, Shear CL and Chremos AN. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. *Archives of Internal Medicine*. 1991; 151(1): 43–49.
- Pierce LR, Wysowski DK and Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. *Journal of the American Medical Association*. 1990;264(1): 71–75.
- Agarwal S and Rao AV. Tomato lycopene and low density lipoprotein oxidation: a human dietary intervention study. *Lipids*. 1998;33(10):981–984.
- Auger PL, Teissedre P and G'eraïn. Dietary wine phenolics catechin, quercetin, and resveratrol efficiently protect hypercholesterolemic hamsters against aortic fatty streak accumulation. *Journal of Agricultural and Food Chemistry*. 2005;53(6):2015–2021.
- Loke WM, Proudfoot JM and Hodgson JM. Specific dietary polyphenols attenuate atherosclerosis in apolipoprotein e-knockout mice by alleviating inflammation and endothelial dysfunction. *Arteriosclerosis, Thrombosis, and Vascular Biology*. 2010;30(4):749–757.
- Joseph B, Dar MA and Kumar V. Bioefficacy of plant extract to control *Fusarium solani* f.sp. *melongena* incident of brinjal wilt. *Global Journal of Biotechnology and Biochemistry*. 2008;3(2):56-59.
- Igwe SA, Akunyili DN and Ogbogu C. Effects of *Solanum melongena* (garden egg) on some visual functions of visually active Igbos of Nigeria. *J Ethnopharmacol*. 2003;86:135-38.
- Nour Basudan. Phytochemical Composition, of *Solanum melongena*, *Solanum melongena*L. and its

- correlation with Bioactive Compounds. *Research Journal of Pharmaceutical, Biological and Chemical Sciences*. 2018;9(4):478.
18. Yang JM and Chen CC. GEMDOCK. A generic evolutionary method for molecular docking. *Proteins: Structure, Function and Bioinformatics*. 2004;55:288-304.
19. Graphical-Automatic Drug Design System for Docking, Screening and Post-Analysis. 2008.